Greater China Strategy | Alpha Picks: February Conviction Calls Chinese equities recovered in January, with the HSI and MSCI China rising 6.9% and 5.0% mom respectively. Given the supportive macro policy environment, we maintain a constructive view on the markets despite the risk of further volatility in February. Accordingly, we are adding Alibaba, Ganfeng Lithium, and Minth to our BUY list, and Meituan to our SELL list. Indonesia Strategy | Alpha Picks: From MSCI Shock To Policy-Driven Rebala...
Chinese equities recovered in January, with the HSI and MSCI China rising 6.9% and 5.0% mom respectively. Given the supportive macro policy environment, we maintain a constructive view on the markets despite the risk of further volatility in February. Accordingly, we are adding Alibaba, Ganfeng Lithium, and Minth to our BUY list, and Meituan to our SELL list.
Greater China Strategy | Alpha Picks: February Conviction Calls Chinese equities recovered in January, with the HSI and MSCI China rising 6.9% and 5.0% mom, respectively. Given the supportive macro policy environment, we maintain a constructive view on the markets despite risk of further volatility in February. Accordingly, we are adding Alibaba, Ganfeng Lithium, and Minth to our BUY list, while adding Meituan to our SELL list. Indonesia Company Results | Bank Negara Indonesia (BBNI IJ/B...
We expect HKEX to achieve a 4% yoy earnings growth in 4Q25, driven by a 16% yoy core revenue growth amid a yoy headline ADT increase, partly offset by a sharp NII decline (-35% yoy) arising from narrowing spread. However, we remain constructive on the ADT outlook for 2026, supported by the global liquidity easing cycle, robust IPO pipeline and potential new stimulus measures in China. Thus, we see further re-rating potential for HKEX. Maintain BUY. Target price: HK$550.00.
Sector Update | Healthcare The sector experienced a fruitful year of innovation in 2025, and we expect globalisation and improving operating efficiency to continue to drive rapid earnings growth for drug innovators and CRO leaders from 2026 onwards. Seeing strong online demand, internet healthcare players are likely to sustain solid revenue and earnings expansion in 2026. We also anticipate that domestic medical device manufacturers will experience a gradual sales growth recovery, fuelled by tec...
Greater China Strategy | Alpha Picks: January Conviction Calls Chinese equities remained in consolidation through December, with the HSI and MSCI China down 0.9% mom and 1.5% mom, respectively, despite last week’s window dressing narrowing losses. Policy signals from the Economic Work Conference broadly met expectations. Looking ahead, we are constructive on 1Q26, supported by a favourable global liquidity cycle and potential macro supportive measures in China. We retain most of our December pic...
Chinese equities remained in consolidation through December, with the HSI and MSCI China down 0.9% mom and 1.5% mom, respectively, despite last week’s window dressing narrowing losses. Policy signals from the Economic Work Conference broadly met expectations. Looking ahead, we are constructive on 1Q26, supported by a favourable global liquidity cycle and potential macro supportive measures in China. We retain most of our December picks, add Baidu and Midea to BUY, and take profit on Li Auto and ...
Greater China Strategy | Alpha Picks: January Conviction Calls Chinese equities remained in consolidation through December, with the HSI and MSCI China down 0.9% mom and 1.5% mom, respectively, despite last week’s window dressing narrowing losses. Policy signals from the Economic Work Conference broadly met expectations. Looking ahead, we are constructive on 1Q26, supported by a favourable global liquidity cycle and potential macro supportive measures in China. We retain most of our December...
Greater China Strategy | Alpha Picks: December Conviction Calls Market consolidation slowed in November as expectations of a 25bp Fed cut improved sentiment. The HSI and MSCI China fell 0.2% and 2.4% mom amid weak data and limited catalysts. While the upcoming Economic Work Conference may offer a catalyst to end this phase, we remain cautious, preferring defensives and oversold names. We add BeOne Medicines, HKEX, NetEase and Plover Bay to BUY, take profit on AIA, and cut losses on Jacobson,...
Highlights We expect global liquidity cycle to remain strong for at least 1H26, following the Fed’s return to policy easing in Sep 25, benefitting emerging market assets and commodities. Chinese equities are likely to rally further, and our index target for MSCI China index target is at 104 pts based on 16.3x 12-month forward PE and 6% EPS growth assumption. We prefer exposure to growth industries like AI/semiconductors, automation/robotics, ADAS and innovative drugs and liquidity proxies ...
HKEX’s net profit grew 56% yoy in 3Q25, 7% ahead of our expectations, driven by solid core revenue on record-high headline ADT and strong IPO momentum. NII fell 13.6% yoy to HK$1.0b, dragged by declining HIBOR and reduced investment gains from the corporate portfolio. We remain constructive on the headline ADT outlook in 2026, helped by the Fed rate cut cycle and strong Southbound flow. Maintain BUY with a higher target price of HK$548.00.
Top Stories Company Results | ECARX Holdings Inc (ECX US /BUY/ US$2.22/Target: US$3.40) ECARX’s 3Q25 earnings made a turnaround, with net profit of US$0.9m in 3Q25, marking its first-ever quarterly profitability. Going forward, we believe earnings will be driven by sales volume growth and product mix optimisation. We maintain our forecast of a net loss of US$49m for 2025 and a turnaround to a net profit of US$36m and US$100m for 2026 and 2027 respectively, based on a 27% revenue CAGR. Maintain ...
Greater China Company Results | ECARX Holdings Inc (ECX US /BUY/ US$2.22/Target: US$3.40) ECARX’s 3Q25 earnings make a turnaround, with net profit of US$0.9m in 3Q25, marking its first-ever quarterly profitability. Going forward, we believe ECARX's earnings will be driven by sales volume growth and product mix optimisation. We maintain our forecast of a net loss of US$49m for 2025 and a turnaround to a net profit of US$36m and US$100m for 2026 and 2027, based on a 27% revenue CAGR. Maintain ...
A director at Hong Kong Exchanges & Clearing bought 2,000 shares at 452.600HKD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
HKEX is expected to deliver strong results in 3Q25, due to a record-high quarter headline ADT of HK$280b (+1.4x yoy) amid a vibrant capital market. In its latest policy address, the Hong Kong government stated that it will optimise listing rules to accommodate the returns of ADR and propose more enhancements on the Connect Scheme. We maintain an optimistic outlook on ADT, driven by Fed rate cut expectations, strong Southbound flows and a strong IPO pipeline. Maintain BUY with a higher target pri...
Top Stories Sector Update | Hong Kong Property The 2025 Policy Address expands the new CIES to include HK$30m-50m worth of residential properties, moderates land supply targets and suspends the Kau Yi Chau project. The North Metropolis needs to accelerate development with innovative measures. Population growth and tourism remain the key policy focus, though local spending lacks direct support. Our pecking order of positive impact on each segment: residential>retail>office. SHKP and Hysan are ou...
Greater China Sector Update | Hong Kong Property The 2025 Policy Address expands the new CIES to include HK$30m-50m worth of residential properties, moderates land supply targets and suspends the Kau Yi Chau project. The North Metropolis needs to accelerate development with innovative measures. Population growth and tourism remain the key policy focus, though local spending lacks direct support. Our pecking order of positive impact on each segment: residential>retail>office. SHKP and Hysan are ...
HKEX’s 2Q25 results were a beat due to better NII on forex gains and prudent cost control. Core revenue came in strong as expected, thanks to high headline ADT in 2Q25. We are positive on the 2H25 ADT outlook, driven by favourable liquidity conditions amid the rate cut cycle, strong Southbound flow and pick-up in IPO pipeline. We expect potential upward revisions to consensus earnings estimates, alongside further valuation re-rating. Maintain BUY with a 10% higher target price of HK$518.00.
KEY HIGHLIGHTS Results Baidu Inc (9888 HK/HOLD/HK$87.25/Target: HK$88.00) Baidu’s 2Q25 earnings missed our expectations. Revenue dropped 4% yoy to Rmb32.7b, in line with consensus estimates. Gross margin dropped 8ppt yoy to 43.9%, below consensus expectations. Non-GAAP operating profit was Rmb4.4b, plunging 41% yoy, while non-GAAP operating profit margin came in at 14%. Non-GAAP net profit slumped 35% yoy to Rmb4.8b, beating consensus forecasts. Maintain HOLD with an unchanged target price of ...
GREATER CHINA Results Baidu Inc (9888 HK/HOLD/HK$87.25/Target: HK$88.00): 2Q25: Earnings missed expectations; release of next-gen Ernie bot in 2H25. Crystal International (2232 HK/BUY/HK$6.08/Target: HK$7.07): 1H25: Continuous margin expansion; strong order visibility into 3Q26. Fuyao Glass Industry Group (3606 HK/BUY/HK$67.50/Target: HK$85.00): 2Q25: Core earnings beat estimates by 8%. Maintain BUY. Raise target price from HK$68.00 to HK$85.00. Hong Kong Exchanges and Clearing (388 HK/BUY/HK$44...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.